PTC THERAPEUTICS INC (PTCT)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PTCT
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PTCT | Director | 65 | ["40 years experience in healthcare investment banking","Managing Director at Morgan Stanley","Vice Chair of Healthcare Investment Banking","Chair of Biotechnology Investment Banking","Experience advising biotechnology companies and pharmaceutical companies"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Ms. Chutter has served as a member of our Board since March 2026. She has over 40 years experience in healthcare investment banking, all at Morgan Stanley & Co. LLC and its affiliates ( Morgan Stanley ), a leading global financial services firm. She was a Managing Director from 1998 to February 2026 and most recently served as Vice Chair of Healthcare Investment Banking from 2020 to February 2026 and Chair of Biotechnology Investment Banking from May 2010 to February 2026. From 1998 to May 2010, she was co-head of Biotechnology Investment Banking and from 1982-1984 and 1986-1997 served in various positions in healthcare investment banking. In her role, she helped build the biotechnology franchise at Morgan Stanley and advised biotechnology companies and pharmaceutical companies on strategic and capital markets considerations, including mergers and acquisitions, initial public offerings, and common stock and convertible financings and valuation analyses. She is a member of the Board of Trustees of The Hospital for Sick Children and a director of Toronto Innovation Acceleration Partners, a not for profit and commercializations hub that translates health science research from member institutions. Ms. Chutter earned an MBA from Harvard Business School and Bachelor of Arts in Commerce and Honors Economics from McGill University. We believe Ms. Chutter is qualified to serve on our Board because of her extensive experience in and knowledge of the biotechnology industry and her leadership experience.